New drug combo targets tough brain cancers in early trial
NCT ID NCT01107522
First seen Nov 01, 2025 · Last updated May 07, 2026 · Updated 19 times
Summary
This early-phase study tests an experimental oral drug called CTO, alone or combined with standard treatments, in 100 adults with advanced solid tumors or aggressive brain cancers (glioblastoma). The main goal is to find the safest dose and understand side effects. Researchers will also check if the drug helps shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS, GLIOBLASTOMA, RECURRENT MALIGNANT GLIOMAS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan-Kettering Cancer Center
New York, New York, 10017, United States
-
New York University
New York, New York, 10016, United States
-
Oregon Health and Sciences University
Portland, Oregon, 97239, United States
-
Providence Cancer Center
Portland, Oregon, 97213, United States
Conditions
Explore the condition pages connected to this study.